Ask HopeStage to review this study with me
Study ID: NCT03788902. We help you review the study, but cannot decide medical eligibility.
CompletedNCT03788902
OT and Social Cognition in Children With ADHD: Impact of MPH
This study is completed. It focuses on ADHD and currently lists study information.
ADHDDrugFrom 6 Years to 12 Years
Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.
Your next step
The official record suggests a remote format run through a university. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and major medical issues that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: February 1, 2014
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Shalvata Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Not clearly listed
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT03788902
- Official title
- Oxytocin and Social Cognition in Children With Attention Deficit Hyperactivity Disorder: Impact of Methylphenidate
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT03788902. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Can be done remotely.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring digital app or tool for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
What practical constraints should I expect?
The likely practical burden appears high. Things to check include long follow-up or multiple visits, medical follow-up. Ask the study team about duration, visits, possible compensation, data access, and what happens if you want to stop.
Who is behind this study?
This study is sponsored by Shalvata Mental Health Center, which appears to be a hospital or academic medical center. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT03785223
Methylphenidate Hydrochloride Controlled Release Capsules for ADHD
This study is completed in Canada. It is testing methylphenidate Hydrochloride Controlled Release Capsules for ADHD.
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
This study is completed in the United States and in Israel. It is testing MG01CI 1400 mg Compared With Placebo for ADHD.
CompletedNCT01177943
A Bioequivalence (BE) Study in Healthy Subjects
This study is completed. It focuses on ADHD and currently lists study information in Japan.